TRADE MARKS ACT 1995
DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS
Re:Application 1041864(5),(35) SASTIN to register a trade mark by Generic Health Pty Ltd and opposition thereto by Merck KGaA.
Delegate: Iain Thompson Representation: Applicant. Written submissions by Justin Vaastra of Arnold Bloch Leibler Opponent: Trevor Stevens of Davies Collison Cave Decision:
- s52 proceedings – ss 44 and 60 – evidence does not establish reputation of trade mark ZACTIN on which the opponent relies; trade marks SASTIN and ZACTIN not deceptively similar, discussion of impact of public policy issues in comparison of trade marks, opposition not established.
Background
Generic Health Pty Ltd (‘the applicant’) of Elsternwick, Victoria, has filed application to register a trade mark, current details of which are:
App No: 1041864
Filing Date: 14 February 2005
Goods:Class: 5 Pharmaceutical preparations and substances
Class: 35Distribution of goods; import services not being transport services
Trade Mark: SASTIN
Following advertisement of acceptance of the trade mark for possible registration on 16 June 2005, Merck KGaA, of Darmstadt, Germany, (‘the opponent’) served and filed Notice of Opposition to registration of the trade mark on 12 September 2005. The opponent has served and filed evidence in support of its opposition in accordance with the Trade Marks Act 1995 (‘the Act’) and regulations thereto. The applicant has not served and filed evidence in answer.
Prior to the hearing before me as a delegate of the Registrar of Trade Marks in Sydney on 16 October 2006, Justin Vaastra of Arnold Bloch Leibler, Solicitors, filed written submissions for the applicant; Trevor Stevens of Davies Collison Cave, Patent & Trade Mark Attorneys, represented the applicant at the hearing.
The submissions of the parties focussed on sections 44 and 60 of the Act.
Evidence
The evidence comprises a statutory declaration by Mark Hurley, Business Development Manager of Alphapharm Pty Ltd, a wholly owned subsidiary of the opponent, with exhibits 1 to 4. There are also four trade declarations served and filed in support of the opposition by dispensing pharmacists Messrs Stephen Thompson, Terry Herfort, Ian Gillard, and William Morgan. I will state now that these trade declarations which are in the form of a questionnaire cannot be regarded as being of high probative weight: the four declarations are in common form with spaces left for the answers to questions, the most relevant one of which is:
Based on my experience within the pharmaceutical industry it is my opinion that the word SASTIN is sufficiently similar to trade mark ZACTIN to cause confusion if applied to the same or similar goods. This opinion is based on the following considerations – that is:
___________________________________________________________________________________________________________________________________________________________________________________________________
The lines underneath are left for a handwritten ‘answer’. However, the printed portion of the proforma declarations do not allow for any other conclusion but that the trade marks are confusingly similar. Additionally, the declarants do not state that they personally would be confused by the similarity of the trade marks – they state that they are of…
Keep reading for free
Create a free CaseChat account to read Merck KGaA v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2007] ATMO 1
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the Hearing Officer were whether the applicant's trade mark SASTIN infringed sections 44 and 60 of the relevant Act. Section 44 typically deals with the registration of trade marks that are identical or deceptively similar to earlier trade marks, while section 60 addresses the use of trade marks that are likely to deceive or cause confusion. The opponent argued that the similarity between SASTIN and ZACTIN would lead to confusion among patients, pharmacists, and doctors, particularly given the serious nature of the conditions treated by the respective pharmaceuticals and the potential for dangerous contraindications.
The Hearing Officer found that the evidence presented by the opponent, particularly the statutory declarations from dispensing pharmacists, lacked sufficient probative weight. These declarations were in a common form, with pre-printed statements suggesting similarity, and did not clearly articulate personal confusion on the part of the declarants. Instead, they expressed an opinion about potential confusion among others. Consequently, the Hearing Officer determined that the opponent had not established its grounds of opposition under sections 44 and 60 of the Act.
As the applicant was successful in the proceedings, the Hearing Officer ordered that the trade mark application number 1041864 proceed to registration one month from the date of the decision, unless an appeal was filed. The opponent was ordered to pay the applicant's costs.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.